Market closed
SELLAS Life Sciences/$SLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About SELLAS Life Sciences
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Ticker
$SLS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
15
ISIN
US81642T2096
Website
SLS Metrics
BasicAdvanced
$145M
-
-$0.38
-
-
Price and volume
Market cap
$145M
52-week high
$1.85
52-week low
$0.95
Average daily volume
1.9M
Financial strength
Current ratio
4.642
Quick ratio
4.123
Long term debt to equity
1.113
Total debt to equity
3.134
Management effectiveness
Return on assets (TTM)
-58.79%
Return on equity (TTM)
-144.90%
Valuation
Price to book
5.24
Price to tangible book (TTM)
5.63
Price to free cash flow (TTM)
-3.414
Growth
Earnings per share change (TTM)
-64.53%
3-year earnings per share growth (CAGR)
-44.35%
SLS News
AllArticlesVideos
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
GlobeNewsWire·2 days ago
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewsWire·4 days ago
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for SELLAS Life Sciences stock?
SELLAS Life Sciences (SLS) has a market cap of $145M as of May 17, 2025.
What is the P/E ratio for SELLAS Life Sciences stock?
The price to earnings (P/E) ratio for SELLAS Life Sciences (SLS) stock is 0 as of May 17, 2025.
Does SELLAS Life Sciences stock pay dividends?
No, SELLAS Life Sciences (SLS) stock does not pay dividends to its shareholders as of May 17, 2025.
When is the next SELLAS Life Sciences dividend payment date?
SELLAS Life Sciences (SLS) stock does not pay dividends to its shareholders.
What is the beta indicator for SELLAS Life Sciences?
SELLAS Life Sciences (SLS) does not currently have a Beta indicator.